glp 1 agonists for alcohol use disorder GLP-1 Agonists: Expanding Horizons in Addiction Treatment GLP‐1 Receptor Agonists for Treating
Description
Real-world Evidence: There is mounting evidence that GLP-1 agonists administered for diabetes or obesity correspond to reduced addiction risk
Under inflammatory conditions in vitro, GLP-1 suppressed the secretion of TNF--associated cytokines and chemokines in BV-2 microglia
6 Kidney disease is common among individuals with type 2 diabetes, as high blood sugar damages kidney blood vessels
Soliqua 100/33 (insulin glargine and lixisenatide injection): Prescribing information
Accessed March 9, 2023
Phase 3 clinical trials compared tirzepatide at 5, 10 and 15 mg doses to semaglutide (1 mg) in a 40-week trial of patients with T2D 51
